SCHEMBL6900995

SCHEMBL6900995

O=C(Nc1cccc2ccccc12)c1ccccc1[N+](=O)[O-]

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.63
CYP3A4 P08684 1/20 0.63
CYP2D6 P10635 1/20 0.63
CYP2C9 P11712 1/20 0.63
CYP2C19 P33261 1/20 0.63
MEN1 O00255 4/20 0.62
KMT2A Q03164 4/20 0.62
LMNA P02545 1/20 0.62
MAPT P10636 1/20 0.62
SMN1; SMN2 Q16637 1/20 0.62
RORC P51449 1/20 0.62
ALOX5 P09917 1/20 0.61
NPC1 O15118 1/20 0.61
RAB9A P51151 1/20 0.61
SIRT6 Q8N6T7 1/20 0.60
KCNMA1 Q12791 1/20 0.59
GAA P10253 1/20 0.59
POLB P06746 1/20 0.58
CHRNB2 P17787 1/20 0.58
CHRNB4 P30926 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7820959 0.88 TP53 (0.56) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL7820965 0.85 POLB (0.65) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL394289 0.85 KCNMA1 (0.79) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL21275460 0.81 RAB9A (0.76) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL11501148 0.81 CYP1A2 (0.51) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL4958316 0.81 KCNMA1 (0.64) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL4958325 0.81 KCNMA1 (0.64) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL28069367 0.81 KCNMA1 (0.78) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL7722700 0.81 ALDH1A1 (0.68) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL11995707 0.80 MAPT (0.67) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1379517-A2 ABCA-1 ELEVATING COMPOUNDS AGAINST CORONARY ARTERY DISEASE OR ATHEROSCLEROSIS CV THERAPEUTICS, INC. (US) 2004-01-14 EP disclosed
US-6548548-B2 ABCA-1 elevating compounds CV THERAPEUTICS, INC. 2003-04-15 US disclosed
US-20020111364-A1 ABCA-1 elevating compounds CV THERAPEUTICS, INC. 2002-08-15 US disclosed
WO-2002046181-A2 ABCA-1 ELEVATING COMPOUNDS AGAINST CORONARY ARTERY DISEASE OR ATHEROSCLEROSIS CV THERAPEUTICS, INC. (US) 2002-06-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020111364-A1 ABCA-1 elevating compounds ABCD3, ABCE1, ABCB4 CYP1A2 947/4885CYP3A4 1597/4885CYP2D6 1350/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.